Novel oxadiazole functionalized pyridopyrimidine derivatives; their anticancer activity and molecular docking studies

A series of novel oxadiazole functionalized pyridopyrimidine derivatives prepared starting from 6-methyl/ethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile 1 . This compound 1 on reaction with sulfuric acid obtained compound 2 , further compound 2 on reaction with chloroacetamide followed by reaction with ethoxy methylene malonic diethyl ester coupling and further cyclization to obtain compound 5 . Compound 5 on reaction with hydrazide hydrate obtained hydrazide derivatives 6 . Compound 6 on reaction with diverse substituted aromatic acids to get oxadiazole derivatives 7a–l . All the final compounds 7a–l evaluated for anticancer activity against four human cancer cell lines such as HeLa—cervical cancer (CCL-2); COLO 205—colon cancer (CCL-222); HepG2—liver cancer (HB-8065); and MCF7—breast cancer (HTB-22) and promising compounds 7d and 7k have been identified and evaluated for molecular docking interactions.